Chromocell Therapeutics Profit Margin

Chromocell Therapeutics (CHRO) currently reports a profit margin of -165.24% as of June 2026. That is below the sector sector average of 19.62%. Use the charts on this page to explore Chromocell Therapeutics's profit margin history and peer comparisons.

Chromocell Therapeutics's profit margin of -165.24% is lower than the its sector sector average of 19.62%. That is roughly 942.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Chromocell Therapeutics's current -165.24% should be judged against industry norms (sector average: 19.62%) and against CHRO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -165.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 19.62%. From there, open related valuation or income-statement pages for Chromocell Therapeutics, and consider following CHRO for alerts when major investors trade the stock.